NCT07784270ClinicalTrials.gov
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
Kurz gefasst
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Phase 31.500 Teilnehmende gesucht230 Studienzentren16 Länder
Kategorien
In 1 Register registriert
- ClinicalTrials.govNCT07784270Diesen Eintrag bei ClinicalTrials.gov öffnenSynchronisiert vor 3 Wochen
Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.
Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.
Interesse an dieser Studie?
Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Not stated: Registered after enrolment began (about 5 days after the recorded start)First posted 2026-08-25; recorded start 2026-08-20
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 1038 other studies in this databaseCounted from the lead sponsor named in the record (AstraZeneca)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 218 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A large study, international in scope: 1,500 participants (target), run at 230 sites, across 16 countries.
How this score is built
- Enrolment32/40
1,500 participants (target)
- Site count25/25
218 sites
- Country count15/15
16 countries
- Planned duration7/10
Planned over about 24 months
- Sponsor scale10/10
AstraZeneca has led 1,017 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Zusammenfassung
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
Erkrankungen
- Obesity or Overweight
- Diabetes Mellitus, Type 2
Eignung
| Geschlecht | Alle |
|---|---|
| Alter | 18 Years – Kein Höchstalter |
| Gesunde Freiwillige | Nein |
Eignung im Wortlaut des Registers
Eignung in einfachen Aussagen
Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.
Studiendesign
| Studientyp | Interventionell |
|---|---|
| Phase | Phase 3 |
| Zuteilung | Randomisiert |
| Interventionsmodell | PARALLEL |
| Primäres Ziel | TREATMENT |
| Verblindung | QUADRUPLE (4) |
| Teilnahme | 1.500 Teilnehmende gesucht |
Sponsor und Mitwirkende
- AstraZeneca Sponsor
Studienarme und Interventionen
- AZD6234 Dose 1EXPERIMENTAL
AZD6234 Dose 1
- AZD6234 Dose 2EXPERIMENTAL
AZD6234 Dose 2
- PlaceboPLACEBO_COMPARATOR
Matching placebo
Interventionen
- Arzneimittel Lenbelintide
IMP injected subcutaneously, once a week. Unit dose strength as per CSP.
- Arzneimittel Placebo
Placebo matching IMP dose injected subcutaneously, once a week.
Endpunkte
Primärer Endpunkt
Percent change in body weight from baseline at 68 weeks of treatment.
To evaluate the effect of AZD6234 compared to placebo in percent body weight change
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Absolute change in weight (kg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on absolute change in weight
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Achievement of at least 5 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 5%
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Achievement of at least 10 % body weight loss from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo in body weight loss of at least 10%
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Change in haemoglobin A1C from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 on haemoglobin A1C change
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Change in waist circumference (cm) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on waist circumference change
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Percent change in triglycerides from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on triglycerides percent change
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Change in systolic blood pressure (mmHg) from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 compared to placebo on systolic blood pressure change
Zeitrahmen 68 weeks
Sekundärer Endpunkt
Percent change in fat mass from baseline at 68 weeks of treatment measured by DXA in the DXA Sub-Study subset
Body Composition Sub-study: To evaluate the effect of AZD6234 compared to placebo on body composition change in the DXA subset of participants
Zeitrahmen 68 weeks
Daten
| Startdatum | 20. August 2026 (tatsächlich) |
|---|---|
| Primärer Abschluss | 9. August 2028 (geschätzt) |
| Abschluss | 9. August 2028 (geschätzt) |
| Erstveröffentlichung | 25. August 2026 (tatsächlich) |
| Zuletzt aktualisiert | 28. Oktober 2026 |
| Ergebnisse veröffentlicht | Im Registereintrag nicht angegeben |
| Status zuletzt bestätigt | Oktober 2026 |
Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.
Standorte
58 Studienzentren rekrutieren
Argentina
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Buenos Aires | Rekrutiert | |
| Research Site | CABA | Rekrutiert | |
| Research Site | Ciudad de Buenos Aires | Rekrutiert | |
| Research Site | Mendoza | Rekrutiert | |
| Research Site | Ramos Mejía | Rekrutierung noch nicht begonnen | |
| Research Site | Rosario | Rekrutiert | |
| Research Site | San Nicolás | Rekrutierung noch nicht begonnen |
Australia
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Botany | Rekrutiert | |
| Research Site | Camberwell | Rekrutiert | |
| Research Site | Charlestown | Rekrutiert | |
| Research Site | Helensvale | Rekrutiert | |
| Research Site | Maroubra | Rekrutiert | |
| Research Site | Waitara | Rekrutiert |
Canada
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Calgary | Alberta | Rekrutiert |
| Research Site | Hamilton | Ontario | Rekrutiert |
| Research Site | Joliette | Quebec | Rekrutiert |
| Research Site | Markham | Ontario | Rekrutiert |
| Research Site | Moncton | New Brunswick | Rekrutiert |
| Research Site | Montreal | Quebec | Rekrutiert |
| Research Site | Montreal | Quebec | Rekrutiert |
| Research Site | North York | Ontario | Rekrutiert |
| Research Site | Québec | Quebec | Rekrutiert |
| Research Site | Sarnia | Ontario | Rekrutiert |
| Research Site | Scarborough Village | Ontario | Rekrutiert |
| Research Site | Stoney Creek | Ontario | Zurückgezogen |
| Research Site | Stouffville | Ontario | Rekrutiert |
| Research Site | Toronto | Ontario | Rekrutiert |
| Research Site | Toronto | Ontario | Rekrutiert |
| Research Site | Trois-Rivières | Quebec | Rekrutiert |
| Research Site | Truro | Nova Scotia | Rekrutiert |
| Research Site | Vancouver | British Columbia | Rekrutiert |
Chile
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Concepción | Rekrutierung noch nicht begonnen | |
| Research Site | Concepción | Rekrutierung noch nicht begonnen | |
| Research Site | Concepción | Rekrutierung noch nicht begonnen | |
| Research Site | Iquique | Rekrutierung noch nicht begonnen | |
| Research Site | Las Condes | Rekrutierung noch nicht begonnen | |
| Research Site | Providencia | Rekrutierung noch nicht begonnen | |
| Research Site | Santiago | Rekrutierung noch nicht begonnen | |
| Research Site | Santiago | Rekrutierung noch nicht begonnen | |
| Research Site | Santiago | Rekrutierung noch nicht begonnen |
China
| Einrichtung | Stadt | Bundesland oder Region | Status |
|---|---|---|---|
| Research Site | Beijing | Rekrutierung noch nicht begonnen | |
| Research Site | Cangzhou | Rekrutierung noch nicht begonnen | |
| Research Site | Changchun | Rekrutierung noch nicht begonnen | |
| Research Site | Chengdu | Rekrutierung noch nicht begonnen | |
| Research Site | Chengdu | Rekrutierung noch nicht begonnen | |
| Research Site | Danyang | Rekrutierung noch nicht begonnen | |
| Research Site | Ganzhou | Rekrutierung noch nicht begonnen | |
| Research Site | Guangzhou | Rekrutierung noch nicht begonnen | |
| Research Site | Huizhou | Rekrutierung noch nicht begonnen | |
| Research Site | Huzhou | Rekrutierung noch nicht begonnen |
180 weitere Studienzentren sind im Registereintrag aufgeführt.
Studiendokumente
In diesem Registereintrag sind keine Dokumente verlinkt.
Änderungen im Zeitverlauf
- 28. Oktober 2026
Abschlussdatum nach hinten verschoben
Primary completion delayed 1 days
2028-08-082028-08-09
- 28. Oktober 2026
Studienzentrum hinzugefügt
3 sites added (230 total)
227230
- 22. September 2026
Status geändert
Status changed from Not yet recruiting to Recruiting
NOT_YET_RECRUITINGRECRUITING
- 22. September 2026
Rekrutierung eröffnet
Recruitment opened
NOT_YET_RECRUITINGRECRUITING
- 22. September 2026
Abschlussdatum nach vorne verschoben
Primary completion advanced 1 days
2028-08-092028-08-08
- 22. September 2026
Studienzentrum hinzugefügt
9 sites added (227 total)
218227